摘要
目的 建立罗沙司他药物利用评价(DUE)标准,评价罗沙司他的临床应用情况,促进该药的合理使用.方法 基于罗沙司他药品说明书,参考相关指南、专家共识,通过德尔菲法建立罗沙司他DUE标准,包括用药指征、用药过程和用药结果等项目.采用回顾性研究方法,对福建省立医院2020年1月1日—2022年12月31日首次使用罗沙司他且用药周期＞1个月的住院患者病历进行用药合理性评价.结果 共纳入175份病历,其中临床应用完全符合评价标准的有14例,用药合理率为8.0％.不合理问题主要为临床结局不适宜(92.0％)、给药剂量不适宜(52.6％)、不良反应监护不适宜(34.9％)、给药时机不适宜(13.1％)、存在药物相互作用(8.7％)、药物转化不适宜(5.7％)、疗效监护不适宜(4.0％).结论 建立的罗沙司他药物评价标准科学、实用、可行,评价结果显示该院罗沙司他在使用过程中不合理率较高,需在用法用量、不良反应监护、给药时机等方面规范罗沙司他的使用.
Abstract
Objective To establish the drug use evaluation(DUE)standards of roxadustat,and to evaluate its clinical application to promote its rational use.Methods Based on the drug labels,referring to relevant guidelines and expert consensus,the DUE criteria for roxadustat were established through the Delphi method,including items such as drug indications,drug use process and the results of medication.A retrospective study was conducted to evaluate the rationality of cases which included inpatients who used roxadustat for the first time from January 1,2020 to December 31,2022,with a medication period of more than one month in Fujian Provincial Hospital.Results A total of 175 medical records were included,of which 14 records were fully met the clinical application evaluation criteria,and the medication reasonable rate was 8.0％.The unreasonable situation were mainly manifested in the inappropriate clinical outcomes(92.0％),the inappropriate use dosages(52.6％),inappropriate monitoring of adverse reactions(34.9％),inappropriate timing of administration(13.1％),drug interactions(8.7％),inappropriate drug conversion(5.7％),inappropriate efficacy monitoring(4.0％).Conclusion The established DUE standards for roxadustat are scientific,practical and feasible,and the evaluation results show a rate of irrationality in the use of roxadustat in the hospital,and it is necessary to standardize the use of roxadustat in terms of dosage,adverse reaction monitoring,and timing of administration.
基金项目
福建医科大学启航基金一般项目(2021QH1310)
维普
万方数据